Reference health
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
14/14 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 14 checked references that resolve
resolves10.1111/dom.13303
Burden of cardio‐renal‐metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry
resolves10.1038/nrneph.2015.173
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
resolves10.2174/1573403X12666160606120254
Type 2 Diabetes and Heart Failure: Challenges and Solutions
resolves10.1053/j.ajkd.2012.07.005
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
resolves10.1056/NEJMoa1504720
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
resolves10.1016/j.ahj.2018.08.016
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
resolves10.1080/19466315.2013.807748
Multiple Testing in Group Sequential Trials Using Graphical Approaches
resolves10.2147/DDDT.S114932
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
The 3 references without a DOI — listed, not checked
no DOI — not checkedEuropean Medicines Agency. Steglatro (ertugliflozin): summary of product characteristics. Hoddesdon United Kingdom: Merck Sharp & Dohme 2018 (https://www.ema.europa.eu/en/documents/product-information/steglatro-epar-product-information_en.pdf).
no DOI — not checkedFood and Drug Administration. Steglatro (ertugliflozin): prescribing information. Whitehouse Station NJ: Merck Sharp & Dohme 2017 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf).
no DOI — not checkedFood and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1056/nejmoa2004967"><img src="https://citestamp.com/citestamped/10.1056/nejmoa2004967/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1056/nejmoa2004967)